SecBot SecBot
PRESS-RELEASE ·Filed May 26, 2026

OLMA

Olema Oncology
NEUTRAL
Impact 4/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

This is a modest pipeline-expansion event for a clinical-stage biotech with no revenue. The collaboration validates OP-3136's combinability but carries no near-term financial catalyst. Watch for ASCO data on May 30, 2026, which could provide the first clinical proof-of-concept for OP-3136. Historical pattern of negative drift on OLMA neutral news suggests caution.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.55
T+0 close · May 26, 2026 · via day close
Latest settled
−16.53%
T+60 · $11.31
Vs SPY
−19.26%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 26 $13.55entry
  2. T+1 · 6mo ago −4.72%α −4.74% · $12.91
  3. T+5 · 6mo ago −21.11%α −22.32% · $10.69
  4. T+20 · 5mo ago −15.42%α −13.48% · $11.46
  5. T+60 · 3mo ago −16.53%α −19.26% · $11.31

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Olema Oncology announced a clinical trial collaboration with Bayer to evaluate its KAT6 inhibitor OP-3136 in combination with darolutamide for metastatic castration-resistant prostate cancer (mCRPC). The Phase 1b/2 study will enroll approximately 36 patients and is expected to start in H2 2026.

Key Facts

  • Olema and Bayer entered a clinical trial collaboration for OP-3136 (KAT6 inhibitor) + darolutamide in mCRPC.
  • Phase 1b/2 study will enroll ~36 patients; initiation expected in H2 2026.
  • Bayer supplies darolutamide; Olema leads the study and retains full global commercial rights to OP-3136.
  • Initial Phase 1 monotherapy data for OP-3136 to be presented at ASCO on May 30, 2026.
  • No upfront or milestone payments disclosed; deal is a drug-supply collaboration only.

Financial Impact

No financial terms disclosed; Bayer provides darolutamide at no cost; Olema bears study costs.

r_and_d_expenses

Risk Factors

  • Phase 1b/2 study may fail to show efficacy or safety in mCRPC.
  • No financial terms disclosed, deal provides no capital infusion.
  • OP-3136 is early-stage (Phase 1); clinical and regulatory risks are high.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3300930

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 26, 2026